+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Kuros Biosciences AG (KURN) - Product Pipeline Analysis, 2020 Update

  • PDF Icon

    Company Profile

  • 32 Pages
  • January 2021
  • GlobalData
  • ID: 5240122
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Kuros Biosciences AG (Kuros Biosciences) is a developer of products for tissue repair and regeneration. It develops a family of bone healing products to address indications in trauma and spine called orthobiologics. It is focused on bone repair for trauma, specifically fracture repair, as well as on spinal fusion. Its pipeline of products are being developed for spinal fusion, fracture repair and as surgical sealants. Kuros Biosciences uses a synthetic matrix technology with reliable and pressure resistant, rapid closure of the damaged tissues. The company’s lead sealant product is Neuroseal. The company operates in Schlieren, Switzerland; Bilthoven, the Netherlands; Burlington, USA and in Konstanz, Germany. Kuros Biosciences is headquartered in Schlieren, Switzerland.

This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.

  • The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
  • The report analyzes all pipeline products in development for the company Kuros Biosciences AG
  • The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
  • The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
  • The report provides detailed description of products in development, technical specification and functions
  • The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.

Reasons to Buy
  • Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
  • Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
  • To formulate effective Research & Development strategies
  • Develop market-entry and market expansion strategies
  • Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
  • Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio

Note: Some sections may be missing if data is unavailable for the company.

Table of Contents

Kuros Biosciences AG Company Overview
  • Kuros Biosciences AG Company Snapshot
  • Kuros Biosciences AG Pipeline Products and Ongoing Clinical Trials Overview
  • Kuros Biosciences AG - Pipeline Analysis Overview
  • Business Description
  • Kuros Biosciences AG - Key Facts
  • Kuros Biosciences AG - Major Products and Services
  • Kuros Biosciences AG Pipeline Products by Development Stage

Kuros Biosciences AG Pipeline Products Overview
  • KUR - 111
  • KUR - 111 Product Overview
  • KUR - 211
  • KUR - 211 Product Overview
  • KUR - 212
  • KUR - 212 Product Overview
  • KUR-112
  • KUR-112 Product Overview
  • KUR-113 - Fracture Repair
  • KUR-113 - Fracture Repair Product Overview
  • KUR-113 - Spinal Fusion
  • KUR-113 - Spinal Fusion Product Overview
  • Neuroseal - Cranial
  • Neuroseal - Cranial Product Overview

Kuros Biosciences AG - Key Competitors
Kuros Biosciences AG - Key Employees
  • Kuros Biosciences AG - Key Employee Biographies

Kuros Biosciences AG - Locations and Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries

Recent Developments
  • Kuros Biosciences AG, Recent Developments
  • Dec 03, 2019: Kuros announces final result of Capital Increase - total gross proceeds of CHF 12.5 million raised
  • Oct 02, 2019: Kuros Biosciences to host key opinion leader meeting in Zurich showcasing its commercial stage advanced Bone Graft MagnetOs
  • Sep 24, 2019: Kuros Biosciences announces full commercial launch of MagnetOs and exhibitor status at North American Spine Society 34 th Annual Meeting
  • Aug 20, 2019: Kuros Biosciences reports results for first half 2019
  • Jul 24, 2019: Kuros announces Gerhard Ries is stepping down as Board member
  • Jul 09, 2019: Kuros Biosciences signs agreement with Surgical Specialties on distribution of MagnetOs in Australia and New Zealand
  • Apr 30, 2019: Kuros Biosciences to propose re-appointment of chairman and board members at Annual General Meeting
  • Apr 12, 2019: Kuros Biosciences reports results for the full year 2018
  • Mar 13, 2019: Kuros Biosciences receives US marketing clearance for intervertebral body fusion device
  • Dec 17, 2018: Kuros ends transformational year with first MagnetOs sales, lead clinical program on track

  • Methodology
  • About the Publisher
  • Contact Us
  • Disclaimer

List of Tables
  • Kuros Biosciences AG Pipeline Products and Ongoing Clinical Trials Overview
  • Kuros Biosciences AG Pipeline Products by Equipment Type
  • Kuros Biosciences AG Pipeline Products by Indication
  • Kuros Biosciences AG, Key Facts
  • Kuros Biosciences AG, Major Products and Services
  • Kuros Biosciences AG Number of Pipeline Products by Development Stage
  • Kuros Biosciences AG Pipeline Products Summary by Development Stage
  • KUR - 111 - Product Status
  • KUR - 111 - Product Description
  • KUR - 211 - Product Status
  • KUR - 211 - Product Description
  • KUR - 212 - Product Status
  • KUR - 212 - Product Description
  • KUR-112 - Product Status
  • KUR-112 - Product Description
  • KUR-113 - Fracture Repair - Product Status
  • KUR-113 - Fracture Repair - Product Description
  • KUR-113 - Spinal Fusion - Product Status
  • KUR-113 - Spinal Fusion - Product Description
  • Neuroseal - Cranial - Product Status
  • Neuroseal - Cranial - Product Description
  • Kuros Biosciences AG, Key Employees
  • Kuros Biosciences AG, Key Employee Biographies
  • Kuros Biosciences AG, Subsidiaries
  • Glossary

List of Figures
  • Kuros Biosciences AG Pipeline Products by Equipment Type
  • Kuros Biosciences AG Pipeline Products by Development Stage

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Polyphor Ltd
  • Novartis AG
  • Medicopharm AG
  • Labatec Pharma SA
  • Genentech USA Inc
  • Geistlich Pharma AG
  • F. Hoffmann-La Roche Ltd
  • Aristo Pharma GmbH
  • Allergan Ltd